ERBB2 and breast carcinoma: Between these groups, there was no difference in rates of pleomorphic ILC, lymphovascular invasion, tumor subtype by ER/PR/HER2 status, grade, presence of lobular carcinoma in situ, or tumor multifocality (Table 2).